Introduction

Bringing a medical device to market requires more than just technical development and bench testing. One of the most critical aspects of regulatory approval is demonstrating that the device is safe and performs as intended. In many cases, this requires clinical evidence, and sometimes, a clinical investigation.

But when exactly is a clinical investigation necessary?

Under regulatory frameworks such as the EU Medical Device Regulation (MDR), manufacturers must justify whether existing data is sufficient—or whether new clinical data must be generated through a formal clinical investigation.

This blog explores when a clinical investigation is required, the factors influencing this decision, and how manufacturers can plan effectively.

Understanding Clinical Evidence Requirements

Clinical evidence is a cornerstone of medical device regulation. It supports claims related to:

• Safety
• Performance
• Clinical benefits

Manufacturers can generate clinical evidence through:

• Scientific literature
• Existing clinical data from equivalent devices
• Post-market data
• Clinical investigations

A clinical investigation becomes necessary when these sources are insufficient to demonstrate conformity with regulatory requirements.

What Is a Clinical Investigation?

A clinical investigation is a systematic study involving human subjects designed to assess the safety and performance of a medical device.

It may be required:

• Before market approval (pre-market)
• After market approval (post-market, e.g., PMCF)

Clinical investigations provide direct evidence of how the device performs in real-world or controlled clinical settings.

Key Situations When a Clinical Investigation Is Required

1. Lack of Sufficient Clinical Data

The most common reason for conducting a clinical investigation is the absence of adequate clinical data.

If manufacturers cannot demonstrate safety and performance using:

• Published literature
• Data from equivalent devices
• Bench and preclinical testing

Then a clinical investigation becomes necessary.

This often happens with new or innovative devices.

2. Novel Technology or Mechanism of Action

Devices that introduce new technology, materials, or mechanisms of action often require clinical investigations.

For example:

• A device using a new energy source
• A novel drug-device combination
• Innovative software-driven functionality

In such cases, existing data may not be sufficient to predict clinical performance.

3. Significant Changes in Intended Use

If a device has a new intended use compared to existing devices, clinical investigation may be required.

For example:

• Expanding use from cosmetic to therapeutic
• Changing the target population
• Introducing new anatomical applications

Even if the device technology is similar, changes in intended use can significantly impact risk and performance.

4. Inability to Demonstrate Equivalence

Under MDR, demonstrating equivalence to another device has become more challenging.

Manufacturers must show equivalence in terms of:

• Clinical characteristics
• Technical characteristics
• Biological characteristics

If equivalence cannot be adequately justified, a clinical investigation is often required.

5. High-Risk Devices

Higher-risk devices (e.g., Class III or implantable devices) generally require more robust clinical evidence.

In many cases, clinical investigations are mandatory because:

• The risk to patients is higher
• The consequences of failure are significant
• Regulatory expectations are stricter

6. Insufficient Bench or Preclinical Testing

Bench testing and preclinical studies are essential, but they cannot always replicate real-world clinical conditions.

A clinical investigation may be required when:

• Human interaction plays a critical role
• The device outcome depends on clinical judgment
• Complex biological responses are involved

7. Regulatory Authority Expectations

Even when manufacturers believe existing data is sufficient, regulatory authorities such as the U.S. Food and Drug Administration or European notified bodies may require additional clinical data.

This can occur when:

• Submitted data does not fully address risks
• Evidence is outdated or not representative
• Data quality is insufficient

When a Clinical Investigation May Not Be Required

Not all devices require clinical investigations.

Manufacturers may avoid clinical studies when:

• Sufficient clinical data already exists
• The device is equivalent to an existing device
• Risks are low and well understood
• Bench testing adequately demonstrates performance

For example, many incremental modifications to existing devices can rely on existing data.

The Role of Clinical Evaluation

The decision to conduct a clinical investigation is made during the clinical evaluation process.

Manufacturers must:

1. Review existing clinical data
2. Identify gaps in evidence
3. Assess whether these gaps impact safety and performance
4. Determine whether additional data is required

If gaps cannot be addressed through literature or existing data, a clinical investigation is justified.

Strategic Considerations for Manufacturers

Early Planning

Regulatory strategy should be defined early in product development.

Early planning helps:

• Identify potential data gaps
• Avoid delays in approval
• Allocate resources effectively

Risk-Based Approach

A risk-based approach is essential.

Higher-risk devices typically require:

• More robust data
• Stronger clinical justification
• Possibly clinical investigations

Leveraging Existing Data

Before deciding on a clinical investigation, manufacturers should explore:

• Literature data
• Equivalent device data
• Post-market surveillance data

This can reduce the need for costly and time-consuming studies.

Engaging with Regulators

Early interaction with regulatory authorities can provide clarity on expectations.

For example:

• Pre-submission meetings with FDA
• Consultation with notified bodies

This helps avoid unnecessary studies or regulatory delays.

Common Challenges

Manufacturers often face challenges such as:

• Demonstrating equivalence under MDR
• Limited access to competitor data
• High cost and time required for clinical studies
• Evolving regulatory expectations

Addressing these challenges requires a well-planned clinical and regulatory strategy.

Final Thoughts

Determining whether a clinical investigation is required is a critical decision in medical device development.

While not all devices need clinical studies, many do—especially when:

• Data is insufficient
• Technology is novel
• Risk is high
• Equivalence cannot be demonstrated

Under frameworks like the EU Medical Device Regulation (MDR), the expectations for clinical evidence have become more stringent, making it essential for manufacturers to carefully evaluate their data and plan accordingly.

Ultimately, a well-structured clinical strategy ensures not only regulatory compliance but also confidence in the safety and performance of the device—which is the foundation of successful market access and patient trust.